Panbio登革熱IGG檢測試劑盒（酶聯免疫法）

廣州健侖生物科技有限公司

本公司為大家供應各種進口品牌登革熱檢測試劑盒，包括澳洲Panbio、美國NovaBios、美國CORTEZ等美國CDC品牌。主要包括膠體金、酶免、PCR等方法學。歡迎咨詢

Panbio登革熱IGG檢測試劑盒（酶聯免疫法）

非洲工作用登革熱試紙

熱帶國家旅游用登革熱檢測試紙

登革熱IgM抗體、登革熱IgG抗體、登革熱NS1抗原、登革熱早期檢測試劑盒

登革熱核酸檢測試劑盒

Panbio公司簡介:
1、1988年成立，2001年在澳大利亞證券交易所上市。
2、Panbio系關于蟲媒感染性疾病及熱帶感染性疾病的專業供貨商。
3、產品面向蟲媒感染性疾病的檢測，在國內疾控系統具有*的認知和認可度。
4、2010年銷售800萬檢測試劑，為30多種疾病提供診斷。

Panbio登革熱介紹：

1、登革熱快速檢測試劑(Dengue Duo Cassette R-DEN03D)
用于定性的快速檢測人群血清、血漿或全血中登革病毒的IgM及IgG抗體。可在15分鐘內檢測結果。

2、登革IgM捕捉ELISA(Dengue IgM Capture ELISA E-DEN01M)
用于定性的檢測人群血清中登革病毒的IgM抗體，用于臨床實驗室對具有持續發燒的登革熱癥狀的病人的輔助診斷。

3、登革IgG捕捉ELISA(Dengo IgG Capture ELISA E-DEN02G)
用于定性檢測血清中登革病毒(血清型1、2、3及4型)的IgG抗體。用于臨床實驗室對繼發登革熱感染的輔助診斷。

4、登革早期ELISA(Dengue Early ELISA E-DEN01P)
用于定性檢測血清中登革病毒的NS1抗原(血清型1、2、3及4型)。用于臨床實驗室對有持續發燒的登革熱癥狀病人的輔助性診斷。

5、登革IgG間接ELISA(Dengue IgG Indirect ELISA E-DEN01G)
用于定性檢測血清中登革病毒(血清型1、2、3及4型)的IgG抗體，用于臨床實驗室對具有持續發燒的登革感染癥狀或接觸史的患者的輔助性診斷。

6、登革IgM & IgG聯檢ELISA(Dengue Duo IgM & IgG Capture ELISA E-DEN01D)
用于定性檢測血清中登革病毒的IgM和IgG抗體。可以區分原發感染與繼發感染。

Dengue產品介紹

Panbio

恢復（重吸收）階段：第三階段在臨界階段結束時開始，并且在等離子體泄漏停止和重新吸收開始時被表征。在此期間，在臨界階段期間從血管內空間泄漏的流體（即血漿和靜脈注射液）被再吸收。表明患者進入康復期的指標包括患者報告的改善的感覺，食欲的恢復，生命體征的穩定（脈搏壓力，強烈的可觸及脈搏），心動過緩，血細胞比容水平恢復正常，尿量增加，以及出現特征性登革熱恢復期（即，有融合的有時瘙癢，瘀斑皮疹與多個小圓形未受影響的皮膚）。在這一點上，必須注意識別表明血管內體積已經穩定（即血漿泄漏已經停止）并且已經開始再吸收的符號。修改靜脈注射液的速率和體積（通常會多次停止靜脈注射液體），以避免流體超載，因為外滲流體返回血管內隔室是重要的。恢復期（再吸收）階段出現的并發癥往往與靜脈注射液管理有關。流體過載可能是由于使用低滲性靜脈注射液，或在康復期間不能使用等滲靜脈注射液。（有關管理的更詳細指導，請參閱下列鏈接中的DHF推薦治療課程。）
雖然感染患者在疾病期間可能會非常不舒服（從眼睛，關節，骨骼，肌肉或頭痛），但是除了流體過載或機械通氣等并發癥外，幾乎所有的DHF患者都會迅速恢復，并及時啟動明智的流體管理和仔細監控。這是由于血管通透性增加的時期受到時間限制（持續24至48小時），并且血管內皮的功能變化似乎*可逆，沒有已知的*性結構缺陷。即使那些并發癥，如果成功管理，經常恢復*沒有后遺癥。
登革熱和登革熱出血熱信息為醫護人員
登革熱是由四種密切相關的登革熱病毒（DENV-1，-2，-3和-4）之一引起的蚊子傳播疾病。用一種血清型DENV的感染為生命中的血清型提供免疫，但對其他血清型沒有提供長期免疫。因此，一個人可以感染多達四次，每次血清型一次。登革熱病毒在家庭環境中由艾滋病蚊子（zui常見的是埃及伊蚊）由人傳播。流行病在西半球定期發生了二百多年。過去三十年來，美國大多數熱帶國家的登革熱傳染和登革熱疫情頻繁增加。
登革熱出血熱和登革熱綜合癥
一些登革熱病人繼續出現登革出血熱（DHF），一種嚴重的，有時是致命的疾病形式。大約在發燒開始消退之后（癥狀發作后通常3-7天），患者可能會發生嚴重疾病的警告征兆。警告標志包括嚴重的腹痛，持續性嘔吐，溫度顯著變化（從發燒到低體溫），出血表現或精神狀態改變（煩躁，混亂或嘔吐）。患者也可能有早期的休克癥狀，包括煩躁不安，寒冷的皮膚粘連，快速的弱脈搏，以及脈壓的收縮（收縮壓？舒張壓）。如果發生任何這些跡象，應告訴登革熱病人返回醫院。
DHF目前由以下四個世界衛生組織（WHO）標準定義：
· 發燒或近期發燒持續2-7天。
· 任何出血表現。
· 血小板減少癥（血小板計數小于100,000 / mm3）。
· 增加血管通透性的證據。
美國衛生和人類服務部
疾病預防與控制中心
臨床診斷
登革熱
經典登革熱或“斷骨熱”，其特征是感染蚊子叮咬后3-14天發生高熱。癥狀包括額頭痛，眼眶后痛，肌痛，關節痛，出血性表現，皮疹和低白細胞計數。患者也可能抱怨厭食癥和惡芯。急性癥狀（如果存在）通常持續約1周，但疲勞，不適和厭食癥可能持續數周。登革熱感染的比例很高，沒有癥狀或癥狀zui少，特別是在兒童和以前沒有登革熱感染史的人群中。
經典登革熱的主要并發癥是發熱性發作和脫水。
治療登革熱強調
· 緩解疼痛癥狀。
· 控制發燒。
· 告訴患者避免阿司匹林和其他非甾體抗炎藥物，因為它們可能會增加出血的風險。
· 提醒患者飲用更多的液體，特別是發燒時。

Panbio

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

想了解更多的Panbio產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

references：

Anticipatory management and monitoring indicators are essential in effectively administering therapies as the patient enters the Critical Phase. New-onset leucopenia (WBC <5,000 cells/mm3) with a lymphocytosis and an increase in atypical lymphocytes indicate that the fever will likely dissipate within the next 24 hours and that the patient is entering into the Critical Phase. Indicators that suggest the patient has already entered the Critical Phase include sudden change from high (>38.0°C) to normal or subnormal temperatures, thrombocytopenia (≤100,000 cells/mm3) with a rising or elevated hematocrit (≥20% increase from baseline), new hypoalbuminemia or hypocholesterolemia, new pleural effusion or ascites, and signs and symptoms of impending or frank shock.

Again, the key to successfully managing patients with DHF and lowering the probability of complications or death is early recognition and anticipatory treatment. Supportive care and timely but measured intravascular volume replacement during the Critical Period are the mainstays of treatment for DHF and DSS. (For more detailed guidance on management guidance, please see the recommended treatment courses for DHF in the links listed below link.) Fortunay, the Critical Period lasts no more than 24 to 48 hours. Most of the complications that arise during this period—such as hemorrhage and metabolic abnormalities (e.g., hypocalcemia, hypoglycemia, hyperglycemia, lactic acidosis, and hyponatremia) are frequently related to prolonged shock. Hence, the principal objective during this period is to prevent prolonged shock and support vital systems until plasma leak subsides. Careful attention must be paid to the type of intravenous fluid (or blood product if transfusion is needed) administered, the rate, and the volume received over time. Frequent monitoring of intravascular volume, vital organ function, and the patient’s response are essential for successful management during the Critical Phase. Monitoring for overt and occult hemorrhage (which may be another source of intravascular depletion) is also important. Transfusion of volume-replacing blood products should be considered if substantial hemorrhage is suspected during this phase. (For more detailed guidance on management, please see the recommended treatment courses for DHF in the links listed below.)

The Convalescent (Reabsorption) Phase: The third phase begins when the Critical Phase ends and is characterized when plasma leak stops and reabsorption begins. During this phase, fluids that leaked from the intravascular space (i.e., plasma and administered intravenous fluids) during the Critical Phase are reabsorbed. Indicators suggesting that the patient is entering the Convalescent Phase include sense of improved well being reported by the patient, return of appetite, stabilizing vital signs (widen pulse pressure, strong palpable pulse), bradycardia, hematocrit levels returning to normal, increased urine output, and appearance of the characteristic Convalescence Rash of Dengue (i.e., a confluent sometimes pruritic, petechial rash with multiple small round islands of unaffected skin). At this point, care must be taken to recognize signs indicating that the intravascular volume has stabilized (i.e., that plasma leak has halted) and that reabsorption has begun. Modifying the rate and volume of intravenous fluids (and often times discontinuing intravenous fluids altogether) to avoid fluid overload as the extravasated fluids return to the intravascular compartment is important. Complications that arise during Convalescent (Reabsorption) Phase are frequently related to the intravenous fluid management. Fluid overload may result from use of hypotonic intravenous fluids or over use or continued use of isotonic intravenous fluids during the Convalescence Phase… (For more detailed guidance on management please see the recommended treatment courses for DHF in the links listed below.)

Although an infected patient will likely have been very uncomfortable (from eye, joint, bone, muscle, or head pain) during the illness, barring complications such as fluid overload or mechanical ventilation nearly all patients with DHF recover rapidly with timely initiation of judicious fluid management and careful monitoring. This is due to the fact that the period of increased vascular permeability is time-limited (lasting 24 to 48 hours) and the functional change in the vascular endothelium appears to be entirely reversible with no known permanent structural defect.  Even those with complications, if managed successfully, often recover fully without sequelae.

Dengue and Dengue Hemorrhagic Fever Information for Health Care Practitioners
Dengue is a mosquito-borne disease caused by any one of four closely related dengue viruses (DENV-1, -2, -3, and -4). Infection with one serotype of DENV provides immunity to that serotype for life, but provides no long-term immunity to other serotypes. Thus, a person can be infected as many as four times, once with each serotype. Dengue viruses are transmitted from person to person by Aedes mosquitoes (most often Aedes aegypti) in the domestic environment. Epidemics have occurred periodically in the Western Hemisphere for more than 200 years. In the past 30 years, dengue transmission and the frequency of dengue epidemics have increased greatly in most tropical countries in the American region.
Dengue Hemorrhagic Fever and Dengue Shock Syndrome
Some patients with dengue fever go on to develop dengue hemorrhagic fever (DHF), a severe and sometimes fatal form of the disease. Around the time the fever begins to subside (usually 3–7 days after symptom onset), the patient may develop warning signs of severe disease. Warning signs include severe abdominal pain, persistent vomiting, marked change in temperature (from fever to hypothermia), hemorrhagic manifestations, or change in mental status (irritability, confusion, or obtundation). The patient also may have early signs of shock, including restlessness, cold clammy skin, rapid weak pulse, and narrowing of the pulse pressure (systolic blood pressure ? diastolic blood pressure). Patients with dengue fever should be told to return to the hospital if they develop any of these signs.
DHF is currently defined by the following four World Health Organization (WHO) criteria:
?  Fever or recent history of fever lasting 2–7 days.
?  Any hemorrhagic manifestation.
?  Thrombocytopenia (plaet countof <100,000/mm3).
?  Evidence of increased vascular permeability.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Diagnosis
Dengue
Classic dengue fever, or “break bone fever,” is characterized by acute onset of high fever 3–14 days after the bite of an infected mosquito. Symptoms include frontal headache, retro-orbital pain, myalgias, arthralgias, hemorrhagic manifestations, rash, and low white blood cell count. The patient also may complain of anorexia and nausea. Acute symptoms, when present, usually last about 1 week, but weakness, malaise, and anorexia may persist for several weeks. A high proportion of dengue infections produce no symptoms or minimal symptoms, especially in children and those with no previous history of having a dengue infection.
The main medical complications of classic dengue fever are febrile seizures and dehydration.
Treatment of dengue fever emphasizes
?  Relieving symptoms of pain.
?  Controlling fever.
?  ling patients to avoid aspirin and other nonsteroidal, anti-inflammatory medications because they may increase the risk for hemorrhage.
?  Reminding patients to drink more fluids, especially when they have a high fever.